CompletedPHASE1, PHASE2NCT05828108
Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia
Studying Diamond-Blackfan anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Principal Investigator
- David J Young, M.D.National Heart, Lung, and Blood Institute (NHLBI)
- Intervention
- Bitopertin(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05828108 on ClinicalTrials.govOther trials for Diamond-Blackfan anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07476183Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan AnemiaApriligen, Inc.
- RECRUITINGNANCT07186179Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)Northwell Health
- RECRUITINGPHASE2NCT03214354Nonmyeloablative Stem Cell Transplant in Children with Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling DonorUniversity of Calgary
- RECRUITINGNCT02720679Investigation of the Genetics of Hematologic DiseasesSt. Jude Children's Research Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT01966367CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell TransplantationDiane George
- RECRUITINGNCT00106015Diamond Blackfan Anemia Registry (DBAR)Northwell Health
- RECRUITINGNANCT00027274Cancer in Inherited Bone Marrow Failure SyndromesNational Cancer Institute (NCI)